慢性唾液分泌過多の世界市場レポート 2025年

慢性唾液分泌過多の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR（複合年間成長率）6.2％で9億7,000万米ドルに成長します。予測期間中の成長は、治療の選択肢に対する意識の高まり、効果的な治療法に対するニーズの高まり、ヘルスケア支出の増加、小児症例の増加、経口ジェルやリキッドに対する需要の高まりといった要因によるものと考えられます。この期間に予想される主要動向には、遠隔モニタリングのための遠隔医療の利用、患者中心のケアモデル、薬理学の革新、言語療法と作業療法の統合、長時間作用型医薬品の開発などがあります。

神経変性疾患の有病率の上昇が慢性唾液分泌過多市場の成長を牽引すると予想されます。神経変性疾患は、脳や脊髄の神経細胞が徐々に変性または死滅することを特徴とする疾患群です。これらの疾患の増加は、遺伝、家族歴、環境の影響、疾患メカニズムのより良い理解、慢セクシャルヘルス状態、社会的・心理的要因などの要因の影響を受けています。慢性唾液分泌過多は、パーキンソン病やALSなどの疾患によく見られる合併症であり、誤嚥を防ぎ、口腔機能を改善し、患者の快適性を高めるための特別な治療が必要となります。例えば、2023年9月にParkinson's UKが発表したところによると、英国では約15万3,000人がパーキンソン病を患っており、人口の高齢化に伴い、この数は20％増加し、2030年には推定17万2,000人になると予想されています。したがって、神経変性疾患の有病率の増加は、慢性唾液分泌過多市場の拡大に寄与することになります。

慢性唾液分泌過多市場に参入している企業は、患者のコンプライアンスを向上させ、小児の慢性唾液分泌過多を管理するための非侵襲的な選択肢を提供し、安全性を高め、副作用を軽減するために、経口溶液などの革新的な治療法の開発に注力しています。内服液剤は、有効成分を溶媒に溶解し、摂取しやすいように製剤化された液体薬剤です。例えば、2023年2月、英国の製薬会社Proveca Pharma Ltd.は、神経障害のある小児の重症慢性唾液分泌過多治療Sialanar（グリコピロニウム臭化物）をフランスで発売しました。本剤は液剤であるため、投与が容易であり、正確な投与が可能であることから、固形剤の投与が困難な小児患者にとって特に有益です。シアラナーは安全性と有効性が実証されており、脳性麻痺などの神経発達症でよくみられる過剰な流涎を抑制することで、QOL（生活の質）を改善します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の慢性唾液分泌過多PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の慢性唾液分泌過多市場：成長率分析
• 世界の慢性唾液分泌過多市場の実績：規模と成長、2019～2024年
• 世界の慢性唾液分泌過多市場の予測：規模と成長、2024～2029年、2034年
• 世界の慢性唾液分泌過多総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の慢性唾液分泌過多市場：治療タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 薬剤療法
• ボツリヌス毒素注射
• 外科的介入
• 医療機器と補助療法
• 世界の慢性唾液分泌過多市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口薬
• 注射による治療
• 局所適用
• 世界の慢性唾液分泌過多市場：患者集団別、実績と予測、2019～2024年、2024～2029年、2034年
• 小児患者
• 成人患者
• 世界の慢性唾液分泌過多市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院と専門クリニック
• リハビリテーションセンター
• 在宅ケア
• 世界の慢性唾液分泌過多市場、薬剤療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 抗コリン薬
• 抗うつ薬
• αアドレナリン作動薬
• 唾液腺調節薬
• 世界の慢性唾液分泌過多市場、ボツリヌス毒素注射のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ボツリヌス毒素A型（ボトックス）
• ボツリヌス毒素B型（ミオブロック）
• 局所唾液腺注射
• 世界の慢性唾液分泌過多市場、外科的介入のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 唾液内視鏡検査
• 唾液腺管拡大術またはステント留置術
• 耳下腺管手術
• 顎下腺摘出術（唾液腺切除術）
• 世界の慢性唾液分泌過多市場、医療機器と補助療法のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 口腔乾燥防止装置
• 唾液分泌刺激装置
• 唇と口の運動
• 人工唾液腺

第7章 地域別・国別分析

• 世界の慢性唾液分泌過多市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の慢性唾液分泌過多市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 慢性唾液分泌過多市場：競合情勢
• 慢性唾液分泌過多市場：企業プロファイル
  • Pfizer Inc.
  • Eisai Co. Ltd.
  • Ipsen Pharmaceuticals Inc.
  • Aurobindo Pharma Limited
  • Shionogi Inc.

第31章 その他の大手企業と革新的企業

• Supernus Pharmaceuticals Inc.
• Granules India Limited
• Hugel Inc.
• Medy-Tox Inc.
• Gufic Biosciences Limited
• US WorldMeds LLC
• Proveca Limited
• Neos Therapeutics Inc.
• Merz Therapeutics GmbH
• Taj Pharma India Limited
• Meitheal Pharmaceuticals
• Clini Experts Services Private Limited
• NeuroHealing Pharmaceuticals Inc.
• ExCEEd Orphan Pharmaceuticals AG
• Solstice Neurosciences Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 慢性唾液分泌過多市場、2029年：新たな機会を提供する国
• 慢性唾液分泌過多市場、2029年：新たな機会を提供するセグメント
• 慢性唾液分泌過多市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Chronic sialorrhea refers to the ongoing excessive production or inability to control saliva, commonly linked to neurological disorders such as Parkinson's disease, cerebral palsy, or ALS. Treatment options include pharmacological therapies, botulinum toxin injections, and surgical procedures aimed at improving oral function, minimizing complications, and enhancing patients' quality of life.

The primary treatment options for chronic sialorrhea are pharmacological therapies, botulinum toxin injections, surgical procedures, medical devices, and assistive therapies. Pharmacological treatments typically involve medications, such as anticholinergics and botulinum toxin injections, to reduce excessive saliva production and alleviate symptoms. These treatments can be administered in various forms, including oral medications, injections, and topical treatments. The patient population for these therapies spans both pediatric and adult groups, with key end users including hospitals, specialty clinics, rehabilitation centers, and homecare environments.

The chronic sialorrhea market research report is one of a series of new reports from The Business Research Company that provides chronic sialorrhea market statistics, including the chronic sialorrhea industry global market size, regional shares, competitors with the chronic sialorrhea market share, detailed chronic sialorrhea market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic sialorrhea industry. This chronic sialorrhea market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic sialorrhea market size has grown strongly in recent years. It will grow from $0.72 billion in 2024 to $0.76 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth during the historic period can be attributed to factors such as the rising prevalence of neurological disorders, population growth, greater awareness and diagnosis, and an increasing demand for non-invasive treatments.

The chronic sialorrhea market size is expected to see strong growth in the next few years. It will grow to $0.97 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth during the forecast period can be attributed to factors such as greater awareness of treatment options, a rising need for effective therapies, increased healthcare spending, growing pediatric cases, and higher demand for oral gels and liquids. Key trends expected in this period include the use of telemedicine for remote monitoring, patient-centered care models, innovations in pharmacology, the integration of speech and occupational therapies, and the development of long-acting pharmaceuticals.

The rising prevalence of neurodegenerative disorders is expected to drive the growth of the chronic sialorrhea market. Neurodegenerative disorders are a group of diseases characterized by the gradual degeneration or death of neurons in the brain and spinal cord. The increase in these disorders is influenced by factors such as genetics, family history, environmental influences, a better understanding of disease mechanisms, chronic health conditions, and social and psychological factors. Chronic sialorrhea is a common complication in conditions such as Parkinson's disease and ALS, requiring specific treatments to prevent aspiration, improve oral function, and enhance patient comfort. For example, in September 2023, Parkinson's UK reported that around 153,000 individuals in the UK are living with Parkinson's disease, and with the aging population, this number is expected to rise by 20% to an estimated 172,000 by 2030. The growing prevalence of neurodegenerative disorders will, therefore, contribute to the expansion of the chronic sialorrhea market.

Companies operating in the chronic sialorrhea market are focusing on developing innovative treatments such as oral solutions to improve patient compliance and provide non-invasive options for managing chronic sialorrhea in children, enhancing safety and reducing side effects. Oral solutions are liquid medications formulated for easy ingestion, with the active ingredient dissolved in a solvent. For instance, in February 2023, Proveca Pharma Ltd., a UK-based pharmaceutical company, launched Sialanar (glycopyrronium bromide) in France for the treatment of severe chronic sialorrhea in children with neurological disorders. This product is available in a liquid form, making it easier to administer and ensuring accurate dosing, which is especially beneficial for pediatric patients who may have difficulty with solid medications. Sialanar offers a proven safety and efficacy profile, improving the quality of life by reducing excessive drooling, a common issue in neurodevelopmental conditions such as cerebral palsy.

In March 2022, Proveca Pharma Ltd. partnered with ExCEEd Orphan to distribute and commercialize Sialanar exclusively in Central and Eastern Europe. This collaboration aims to make Sialanar more widely available for treating chronic sialorrhea in children with neurodisabilities across eight countries in the region. The partnership addresses an unmet medical need and helps improve the quality of life for patients struggling with excessive drooling due to neurological disorders. ExCEEd Orphan S.R.O., based in the Czech Republic, specializes in helping patients with rare diseases, such as chronic sialorrhea.

Major players in the chronic sialorrhea market are Pfizer Inc., Eisai Co. Ltd., Ipsen Pharmaceuticals Inc., Aurobindo Pharma Limited, Shionogi Inc., Supernus Pharmaceuticals Inc., Granules India Limited, Hugel Inc., Medy-Tox Inc., Gufic Biosciences Limited, US WorldMeds LLC, Proveca Limited, Neos Therapeutics Inc., Merz Therapeutics GmbH, Taj Pharma India Limited, Meitheal Pharmaceuticals, Clini Experts Services Private Limited, NeuroHealing Pharmaceuticals Inc., ExCEEd Orphan Pharmaceuticals AG, and Solstice Neurosciences Inc.

North America was the largest region in the chronic sialorrhea market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chronic sialorrhea report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic sialorrhea market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic sialorrhea market consists of revenues earned by entities by providing services such as medical treatment services, non-surgical interventions, and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic sialorrhea market also includes sales of neurostimulation devices, resection kits, absorbent clothing and bibs, and customized oral prosthetics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Sialorrhea Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic sialorrhea market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic sialorrhea ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic sialorrhea market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Pharmacological Treatments; Botulinum Toxin Injections; Surgical Interventions; Medical Devices And Assistive Therapies
• 2) By Route Of Administration: Oral Medications; Injectable Treatments; Topical Applications
• 3) By Patient Population: Pediatric Patients; Adult Patients
• 4) By End-User: Hospitals And Specialty Clinics; Rehabilitation Centers; Homecare Settings
• Subsegments:
• 1) By Pharmacological Treatments: Anticholinergic Medications; Antidepressants; Alpha-adrenergic Agonists; Salivary Gland Modulators
• 2) By Botulinum Toxin Injections: Botulinum Toxin Type A (Botox); Botulinum Toxin Type B (Myobloc); Localized Salivary Gland Injections
• 3) By Surgical Interventions: Sialendoscopy; Salivary Gland Duct Dilation or Stenting; Parotid Duct Surgery; Submandibular Gland Removal (Sialadenectomy)
• 4) By Medical Devices And Assistive Therapies: Oral Dryness Devices; Salivary Stimulation Devices; Lip and Mouth Exercises; Artificial Salivary Glands
• Companies Mentioned: Pfizer Inc.; Eisai Co. Ltd.; Ipsen Pharmaceuticals Inc.; Aurobindo Pharma Limited; Shionogi Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chronic Sialorrhea Market Characteristics

3. Chronic Sialorrhea Market Trends And Strategies

4. Chronic Sialorrhea Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Chronic Sialorrhea Growth Analysis And Strategic Analysis Framework

• 5.1. Global Chronic Sialorrhea PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Chronic Sialorrhea Market Growth Rate Analysis
• 5.4. Global Chronic Sialorrhea Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Chronic Sialorrhea Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Chronic Sialorrhea Total Addressable Market (TAM)

6. Chronic Sialorrhea Market Segmentation

• 6.1. Global Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmacological Treatments
• Botulinum Toxin Injections
• Surgical Interventions
• Medical Devices And Assistive Therapies
• 6.2. Global Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Medications
• Injectable Treatments
• Topical Applications
• 6.3. Global Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric Patients
• Adult Patients
• 6.4. Global Chronic Sialorrhea Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Specialty Clinics
• Rehabilitation Centers
• Homecare Settings
• 6.5. Global Chronic Sialorrhea Market, Sub-Segmentation Of Pharmacological Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anticholinergic Medications
• Antidepressants
• Alpha-adrenergic Agonists
• Salivary Gland Modulators
• 6.6. Global Chronic Sialorrhea Market, Sub-Segmentation Of Botulinum Toxin Injections, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Botulinum Toxin Type A (Botox)
• Botulinum Toxin Type B (Myobloc)
• Localized Salivary Gland Injections
• 6.7. Global Chronic Sialorrhea Market, Sub-Segmentation Of Surgical Interventions, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sialendoscopy
• Salivary Gland Duct Dilation or Stenting
• Parotid Duct Surgery
• Submandibular Gland Removal (Sialadenectomy)
• 6.8. Global Chronic Sialorrhea Market, Sub-Segmentation Of Medical Devices And Assistive Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Dryness Devices
• Salivary Stimulation Devices
• Lip and Mouth Exercises
• Artificial Salivary Glands

7. Chronic Sialorrhea Market Regional And Country Analysis

• 7.1. Global Chronic Sialorrhea Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Chronic Sialorrhea Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chronic Sialorrhea Market

• 8.1. Asia-Pacific Chronic Sialorrhea Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chronic Sialorrhea Market

• 9.1. China Chronic Sialorrhea Market Overview
• 9.2. China Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chronic Sialorrhea Market

• 10.1. India Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chronic Sialorrhea Market

• 11.1. Japan Chronic Sialorrhea Market Overview
• 11.2. Japan Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chronic Sialorrhea Market

• 12.1. Australia Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chronic Sialorrhea Market

• 13.1. Indonesia Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chronic Sialorrhea Market

• 14.1. South Korea Chronic Sialorrhea Market Overview
• 14.2. South Korea Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chronic Sialorrhea Market

• 15.1. Western Europe Chronic Sialorrhea Market Overview
• 15.2. Western Europe Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chronic Sialorrhea Market

• 16.1. UK Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chronic Sialorrhea Market

• 17.1. Germany Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chronic Sialorrhea Market

• 18.1. France Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chronic Sialorrhea Market

• 19.1. Italy Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chronic Sialorrhea Market

• 20.1. Spain Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chronic Sialorrhea Market

• 21.1. Eastern Europe Chronic Sialorrhea Market Overview
• 21.2. Eastern Europe Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chronic Sialorrhea Market

• 22.1. Russia Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chronic Sialorrhea Market

• 23.1. North America Chronic Sialorrhea Market Overview
• 23.2. North America Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chronic Sialorrhea Market

• 24.1. USA Chronic Sialorrhea Market Overview
• 24.2. USA Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chronic Sialorrhea Market

• 25.1. Canada Chronic Sialorrhea Market Overview
• 25.2. Canada Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chronic Sialorrhea Market

• 26.1. South America Chronic Sialorrhea Market Overview
• 26.2. South America Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chronic Sialorrhea Market

• 27.1. Brazil Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chronic Sialorrhea Market

• 28.1. Middle East Chronic Sialorrhea Market Overview
• 28.2. Middle East Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chronic Sialorrhea Market

• 29.1. Africa Chronic Sialorrhea Market Overview
• 29.2. Africa Chronic Sialorrhea Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Chronic Sialorrhea Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Chronic Sialorrhea Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chronic Sialorrhea Market Competitive Landscape And Company Profiles

• 30.1. Chronic Sialorrhea Market Competitive Landscape
• 30.2. Chronic Sialorrhea Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Eisai Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Ipsen Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Aurobindo Pharma Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Shionogi Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Chronic Sialorrhea Market Other Major And Innovative Companies

• 31.1. Supernus Pharmaceuticals Inc.
• 31.2. Granules India Limited
• 31.3. Hugel Inc.
• 31.4. Medy-Tox Inc.
• 31.5. Gufic Biosciences Limited
• 31.6. US WorldMeds LLC
• 31.7. Proveca Limited
• 31.8. Neos Therapeutics Inc.
• 31.9. Merz Therapeutics GmbH
• 31.10. Taj Pharma India Limited
• 31.11. Meitheal Pharmaceuticals
• 31.12. Clini Experts Services Private Limited
• 31.13. NeuroHealing Pharmaceuticals Inc.
• 31.14. ExCEEd Orphan Pharmaceuticals AG
• 31.15. Solstice Neurosciences Inc.

32. Global Chronic Sialorrhea Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Sialorrhea Market

34. Recent Developments In The Chronic Sialorrhea Market

35. Chronic Sialorrhea Market High Potential Countries, Segments and Strategies

• 35.1 Chronic Sialorrhea Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Chronic Sialorrhea Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Chronic Sialorrhea Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer